| | english | español | français |
Go to record ID

  Home|Finding Information|Record details   Printer-friendly version

Modified Organism
Vaccine against Aujeszky's Disease
Record information and status
Record ID
Date of creation
2009-08-10 16:22 UTC (manoela.miranda@cbd.int)
Date of last update
2012-06-27 18:30 UTC (dina.abdelhakim@cbd.int)
Date of publication
2012-06-27 18:30 UTC (dina.abdelhakim@cbd.int)

Living Modified Organism identity
The image below identifies the LMO through its unique identifier, trade name and a link to this page of the BCH. Click on it to download a larger image on your computer. For help on how to use it go to the LMO quick-links page.

LMO name
Vaccine against Aujeszky's Disease
Transformation event
Not available
Vemie Veterinär Chemie GmbH
Tackweg 11
Germany, 47918
Two genes (glycoprotein gene and thymidine kinase gene) of the Pseudorabies virus (PRV) were deleted in this LMO to produce the animal vaccine "Nobi-Porvac Aujeszky live (gl, tk) (with Diluvac forte)". This vaccine is intended for immunisation of pigs against Aujeszky disease.
Recipient Organism or Parental Organisms
The term Recipient organism refers to an organism (either already modified or non-modified) that was subjected to genetic modification, whereas Parental organisms refers to those that were involved in cross breeding or cell fusion.
Suid alphaherpesvirus 1 - SHV-1
Point of collection or acquisition of the recipient organism
SHV-1 strain used is Begonia
Characteristics of the transformation process
Introduced or modified genetic elements
Some of these genetic elements may be present as fragments or truncated forms. Please see notes below, where applicable.
gI Glycoprotein - Suid alphaherpesvirus 1 - SHV-1
Production of medical or pharmaceutical compounds (human or animal) - Vaccines
PK Protein Kinase - Suid alphaherpesvirus 1 - SHV-1
Production of medical or pharmaceutical compounds (human or animal) - Vaccines
Notes regarding the genetic elements introduced or modified in this LMO
The gI and PK genes are deleted from the native SHV-1 to produce an attenuated virus to be used as a vaccine.
LMO characteristics
Modified traits
Common use(s)
  • Vaccine